Trial · NCT01411085

Risperidone and Desipramine in Alcohol Use and Schizophrenia

NCT01411085, Phase 2, Completed, Dartmouth-Hitchcock Medical Center; results first posted 2018-03-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Risperidone and Desipramine in Alcohol Use and Schizophrenia. Trials, record NCT01411085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01411085

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Risperidone and Desipramine in Alcohol Use and Schizophrenia
NCT number: NCT01411085
Status: Completed
Phases: Phase 2
Enrollment: 12 participants, actual
Lead sponsor: Dartmouth-Hitchcock Medical Center
Conditions: Schizophrenia, Alcoholism, Dual Diagnosis
Interventions: Risperidone + Desipramine
First posted: 2011-08-08
Last updated: 2018-03-23
Results first posted: 2018-03-23

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Timeline Followback Assessing Number of Drinks Per Week	Weekly for 14 weeks, using data from last 8 weeks	Alcohol/other substance use (including tobacco) will be assessed primarily by weekly self-report using the Timeline Followback (TLFB) method enhanced by procedures to strengthen the reliability and validity of this measure. It involves asking participants to retrospectively estimate their alcohol and other substance use.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Timeline Followback Assessing Number of Drinks Per Week	Weekly for 14 weeks, using data from last 8 weeks	The analysis was performed on all completers (N=7).	Drinks per week	MEAN

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Timeline Followback Assessing Number of Drinks Per Week	Risperidone + Desipramine		35.9	Standard Deviation 20.4	Drinks per week

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Risperidone + Desipramine	10
Overall Study	COMPLETED	Risperidone + Desipramine	7
Overall Study	NOT COMPLETED	Risperidone + Desipramine	3

Source ClinicalTrials.gov

Adverse events29

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anxiety	Psychiatric disorders	Risperidone + Desipramine	1	10	2
other	Depression	Psychiatric disorders	Risperidone + Desipramine	1	10	1
other	Diarrehea	Gastrointestinal disorders	Risperidone + Desipramine	1	10	1
other	Dizziness	General disorders	Risperidone + Desipramine	1	10	1
other	Dry Mouth	Gastrointestinal disorders	Risperidone + Desipramine	2	10	2
other	Fall	Injury, poisoning and procedural complications	Risperidone + Desipramine	2	10	2
other	Gum Infection	Infections and infestations	Risperidone + Desipramine	1	10	1
other	Hypertension	Cardiac disorders	Risperidone + Desipramine	1	10	1
other	Increased appetite	Gastrointestinal disorders	Risperidone + Desipramine	1	10	1
other	Insomnia	Psychiatric disorders	Risperidone + Desipramine	1	10	1

1 to 10 of 29Source ClinicalTrials.gov

See all 29 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Risperidone + Desipramine
Total, other adverse events	Risperidone + Desipramine	10	10
Total, serious adverse events	Risperidone + Desipramine	3	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21AA019534	Alcoholism and Schizophrenia: A Translational Approach to Treatment	GREEN, ALAN I	DARTMOUTH COLLEGE	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2011 to 2012

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01411085

GET https://conductscience.org/api/trials/v1/NCT01411085/events?page=2

API reference For AI assistants